Cargando…

Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies

BACKGROUND: Immune checkpoint blockade (ICB) has achieved unprecedented success in treating multiple cancer types. However, clinical benefit remains modest for most patients with solid malignancies due to primary or acquired resistance. Tumor-intrinsic loss of major histocompatibility complex class...

Descripción completa

Detalles Bibliográficos
Autores principales:	Minnar, Christine M, Chariou, Paul L, Horn, Lucas A, Hicks, Kristin C, Palena, Claudia, Schlom, Jeffrey, Gameiro, Sofia R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240938/ https://www.ncbi.nlm.nih.gov/pubmed/35764364 http://dx.doi.org/10.1136/jitc-2022-004561

Ejemplares similares

Tumour-targeted interleukin-12 and entinostat combination therapy improves cancer survival by reprogramming the tumour immune cell landscape
por: Hicks, Kristin C., et al.
Publicado: (2021)

Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication
por: Horn, Lucas A., et al.
Publicado: (2022)

Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
por: Knudson, Karin M, et al.
Publicado: (2020)

Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity
por: Horn, Lucas A, et al.
Publicado: (2020)

Therapeutic depletion of CCR8(+) tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy
por: Van Damme, Helena, et al.
Publicado: (2021)

Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment
por: Acúrcio, Rita C., et al.
Publicado: (2022)

Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade
por: Ju, Fei, et al.
Publicado: (2022)

Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers
por: Nebot-Bral, Laetitia, et al.
Publicado: (2022)

KLF12 overcomes anti-PD-1 resistance by reducing galectin-1 in cancer cells
por: Zheng, Yujia, et al.
Publicado: (2023)

IMMU-13. Dual CTLA4/ PD-1 blockade improves survival for replication-repair deficient high-grade gliomas failing single agent PD-1 inhibition: An IRRDC study
por: Das, Anirban, et al.
Publicado: (2022)

Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors
por: Zhang, Xiaozhen, et al.
Publicado: (2022)

Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status
por: Camy, Florian, et al.
Publicado: (2020)

Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa
por: Ozawa, Yohei, et al.
Publicado: (2021)

Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer
por: Qiu, Xin, et al.
Publicado: (2023)

Dickkopf 1 impairs the tumor response to PD-1 blockade by inactivating CD8+ T cells in deficient mismatch repair colorectal cancer
por: Sui, Qiaoqi, et al.
Publicado: (2021)

CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer
por: Yang, Moran, et al.
Publicado: (2021)

The identification of TCF1(+) progenitor exhausted T cells in THRLBCL may predict a better response to PD-1/PD-L1 blockade
por: Tabanelli, Valentina, et al.
Publicado: (2022)

High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis
por: Jung, Jaeyun, et al.
Publicado: (2023)

PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
por: Šmahel, Michal
Publicado: (2017)

CD8(+)PD-1(+) to CD4(+)PD-1(+) ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
por: Duchemann, Boris, et al.
Publicado: (2022)

Hyperprogressive disease during PD-1 blockade in patients with advanced pancreatic cancer
por: Chen, Shiyun, et al.
Publicado: (2023)

Combining histological grade, TILs, and the PD-1/PD-L1 pathway to identify immunogenic tumors and de-escalate radiotherapy in early breast cancer: a secondary analysis of a randomized clinical trial
por: Stenmark Tullberg, Axel, et al.
Publicado: (2023)

Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
por: Starzer, Angelika M, et al.
Publicado: (2021)

Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
por: Rozenblit, Mariya, et al.
Publicado: (2020)

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine
por: Baldelli, Elisa, et al.
Publicado: (2021)

Comparison of PD-L1 tumor cell expression with 22C3, 28-8, and SP142 IHC assays across multiple tumor types
por: Maule, Jake G, et al.
Publicado: (2022)

Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade
por: Jung, Bo-Kyeong, et al.
Publicado: (2020)

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
por: Robbins, Yvette, et al.
Publicado: (2021)

Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck
por: Zandberg, Dan P, et al.
Publicado: (2021)

NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
por: Yan, Sen, et al.
Publicado: (2022)

Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer
por: Wang, Yumeng, et al.
Publicado: (2022)

Enhanced B7-H4 expression in gliomas with low PD-L1 expression identifies super-cold tumors
por: Chen, Di, et al.
Publicado: (2020)

In PD-1+ human colon cancer cells NIVOLUMAB promotes survival and could protect tumor cells from conventional therapies
por: Ieranò, Caterina, et al.
Publicado: (2022)

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances
por: Lind, Hanne, et al.
Publicado: (2020)

An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade
por: Zuo, Shuguang, et al.
Publicado: (2021)

Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy
por: Munoz, Luis Enrique, et al.
Publicado: (2021)

Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity
por: Nawaf, Maher G., et al.
Publicado: (2017)

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
por: Banchereau, Romain, et al.
Publicado: (2021)

Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer
por: Moutafi, Myrto K, et al.
Publicado: (2022)

Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
por: Lopez de Rodas, Miguel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s2nvkp959uuj9rrngrsaehg17v